Rituximab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

@inproceedings{Muoz2015RituximabIT,
  title={Rituximab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis},
  author={Sebasti{\'a}n A Mu{\~n}oz and Ignacio J. Gandino and Alberto Omar Orden and Alberto Allievi},
  year={2015}
}
Abstract Background The general consensus is that for patients with EGPA with poor prognosis, intensive therapy with both GC and CF is indicated. The maintenance of remission is made with GC and AZA. A considerable number of patients with EGPA are refractory to first line therapy, experience dose-limiting side effects or relapse. In clinical trials, RTX was effective for the treatment of ANCA-associated vasculitis. However, patients with a diagnosis of EGPA were not included. Objective To… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Biologics for childhood systemic vasculitis

  • Pediatric Nephrology
  • 2018
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Eosinophile Granulomatose und Polyangiitis – Diagnostik und Therapie

C. Kroegel, H. Slevogt, +3 authors Ulrich Costabel
  • Der Pneumologe
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND